UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

7th Annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland

mAbs, 2012, Vol.4 (2), p.134-152

2012

Volltextzugriff (PDF)

7th Annual European Antibody Congress 2011: November 29–December 1, 2011, Geneva, Switzerland

mAbs, 2012-03, Vol.4 (2), p.134-152

2012

Volltextzugriff (PDF)

8 th Annual European Antibody Congress 2012: November 27–28, 2012, Geneva, Switzerland

mAbs, 2013-05, Vol.5 (3), p.339-357

2013

Volltextzugriff (PDF)

8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland

mAbs, 2013, Vol.5 (3), p.339

2013

Volltextzugriff (PDF)

8th Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland

mAbs, 2013, Vol.5 (3), p.339-357

2013

Volltextzugriff (PDF)

8th Annual European Antibody Congress 2012: November 27–28, 2012, Geneva, Switzerland

mAbs, 2013-05, Vol.5 (3), p.339-357

2013

Volltextzugriff (PDF)

9th Annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland

mAbs, 2014, Vol.6 (2), p.309-326

2014

Volltextzugriff (PDF)

9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland

mAbs, 2014-03, Vol.6 (2), p.309-326

2014

Volltextzugriff (PDF)

Abstract 1209: Istiratumab (MM-141), a bispecific antibody targeting IGF-1R and ErbB3, inhibits pro-survival signaling in vitro and potentiates the activity of standard of care chemotherapy in vivo in ovarian cancer models

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.1209-1209

2016

Volltextzugriff (PDF)

Abstract 2077A: MM141, a novel bispecific antibody co-inhibitor of IGF-1R and ErbB3, inhibits the proliferation of melanoma cells

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2077-2077A

2013

Volltextzugriff (PDF)

Abstract 2719: MM-141, a novel bispecific antibody co-targeting IGF-1R and ErbB3, blocks ligand-induced signaling and demonstrates antitumor activity

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2719-2719

2012

Volltextzugriff (PDF)

Abstract 750: Nanoliposomal targeting of Ephrin receptor A2 (EphA2): Clinical translation

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.750-750

2016

Volltextzugriff (PDF)

Abstract A89: Istiratumab (MM-141), a bispecific antibody co-targeting IGF-1R and ErbB3, potentiates the activity of immune checkpoint inhibitors

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.A89-A89

2015

Volltextzugriff (PDF)

Abstract B205: Therapeutically targeting redundant, growth factor-induced prosurvival signaling with MM-141, a novel bispecific antibody targeting IGF-1R and ErbB3

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.B205-B205

2011

Volltextzugriff (PDF)

Abstract C169: MM-141, a bispecific antibody inhibitor of PI3K/AKT/mTOR, attenuates tumor growth and potentiates everolimus in mouse models of anti-hormonal therapy-resistant ER/PR+ breast cancer

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.C169-C169

2013

Volltextzugriff (PDF)

Abstract CT237: Preclinical characterization and first-in-human study of MM-141, a dual antibody inhibitor of IGF-1R and ErbB3

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.CT237-CT237

2015

Volltextzugriff (PDF)

Abstract POSTER-THER-1411: MM-141, an IGF-1R and ErbB3 directed tetravalent bispecific antibody, inhibits ovarian cancer cell growth in vitro

Clinical cancer research, 2015-08, Vol.21 (16_Supplement), p.POSTER-THER-1411-POSTER-THER-1411

2015

Volltextzugriff (PDF)

Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML)

PLoS genetics, 2009-02, Vol.5 (2), p.e1000368-e1000368

2009

Volltextzugriff (PDF)

Adaptive Mutations in the JC Virus Protein Capsid Are Associated with Progressive Multifocal Leukoencephalopathy (PML): e1000368

PLoS genetics, 2009-02, Vol.5 (2)

2009

Volltextzugriff (PDF)

Affinity enhancement of an in vivo matured therapeutic antibody using structure‐based computational design

Protein science, 2006-05, Vol.15 (5), p.949-960

2006

Volltextzugriff (PDF)

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR

mAbs, 2009-03, Vol.1 (2), p.128-141

2009

Volltextzugriff (PDF)

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR

mAbs, 2009-03, Vol.1 (2), p.128-141

2009

Volltextzugriff (PDF)

Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework

Methods (San Diego, Calif.), 2014-01, Vol.65 (1), p.68-76

2014

Volltextzugriff (PDF)

Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models

Nature biomedical engineering, 2019-04, Vol.3 (4), p.264-280

2019

Volltextzugriff (PDF)

Comparative analysis Crimean, Moldavian and Kuban Persian walnut collections genetic variability by SSR-markers

Scientia horticulturae, 2019-07, Vol.253, p.322-326

2019

Volltextzugriff (PDF)

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(88)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(91)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

7th Annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland

7th Annual European Antibody Congress 2011: November 29–December 1, 2011, Geneva, Switzerland

8 th Annual European Antibody Congress 2012: November 27–28, 2012, Geneva, Switzerland

8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland

8th Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland

8th Annual European Antibody Congress 2012: November 27–28, 2012, Geneva, Switzerland

9th Annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland

9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland

Abstract 1209: Istiratumab (MM-141), a bispecific antibody targeting IGF-1R and ErbB3, inhibits pro-survival signaling in vitro and potentiates the activity of standard of care chemotherapy in vivo in ovarian cancer models

Abstract 2077A: MM141, a novel bispecific antibody co-inhibitor of IGF-1R and ErbB3, inhibits the proliferation of melanoma cells

Abstract 2719: MM-141, a novel bispecific antibody co-targeting IGF-1R and ErbB3, blocks ligand-induced signaling and demonstrates antitumor activity

Abstract 750: Nanoliposomal targeting of Ephrin receptor A2 (EphA2): Clinical translation

Abstract A89: Istiratumab (MM-141), a bispecific antibody co-targeting IGF-1R and ErbB3, potentiates the activity of immune checkpoint inhibitors

Abstract B205: Therapeutically targeting redundant, growth factor-induced prosurvival signaling with MM-141, a novel bispecific antibody targeting IGF-1R and ErbB3

Abstract C169: MM-141, a bispecific antibody inhibitor of PI3K/AKT/mTOR, attenuates tumor growth and potentiates everolimus in mouse models of anti-hormonal therapy-resistant ER/PR+ breast cancer

Abstract CT237: Preclinical characterization and first-in-human study of MM-141, a dual antibody inhibitor of IGF-1R and ErbB3

Abstract POSTER-THER-1411: MM-141, an IGF-1R and ErbB3 directed tetravalent bispecific antibody, inhibits ovarian cancer cell growth in vitro

Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML)

Adaptive Mutations in the JC Virus Protein Capsid Are Associated with Progressive Multifocal Leukoencephalopathy (PML): e1000368

Affinity enhancement of an in vivo matured therapeutic antibody using structure‐based computational design

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR

Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework

Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models

Comparative analysis Crimean, Moldavian and Kuban Persian walnut collections genetic variability by SSR-markers

Suchergebnisse filtern